Abstract
Background
Chemokines are key regulators of leukocyte traffic in various forms of inflammation and reperfusion injury. There is emerging evidence that the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) importantly contributes to the up-regulation of a variety of proinflammatory signal transduction pathways and associated genes.
Materials and Methods
We tested whether the expression of the chemokines macrophage inflammatory protein (MIP)-1α and MIP-2 are under the control of PARP during inflammation.
Results
Pharmacologic inhibition of PARP and genetic deletion of PARP suppressed the expression of MIP-1α and MIP-2 protein and mRNA in immunostimulated cultured murine macrophages and fibroblasts. PARP inhibition also suppressed the activation of NF-κB, a key transcription factor known to be involved in the generation of chemokines in immunostimulated cells. In vivo, in various models of local and systemic inflammation, including dextran sodium sulfate-induced colitis and endotoxic shock, pharmacologic inhibition of PARP suppressed the expression of MIP-1α and MIP-2. These effects were associated with a marked suppression of the inflammatory response, including an attenuation of neutrophil infiltration into inflamed organs.
Conclusions
A combination approach of pharmacologic inhibition and genetic deletion revealed that the major isoform of PARP (PARP-1) plays a predominant, but not exclusive, role in the regulation of chemokine production in vivo. Suppression of chemokine expression may be a novel mode of anti-inflammatory action of PARP inhibition.
Similar content being viewed by others
References
De Murcia G, Shall S. (eds) (2000) From DNA Damage and Stress Signaling to Cell Death: Poly ADP-Ribosylation Reactions. Oxford: Oxford University Press.
Szabo C. (ed) (2000) Cell Death: The role of PARP. Boca Raton, FL: CRC Press.
Smith S. (2001) The world according to PARP. Trends Biochem. Sci. 26: 174–179.
Szabo C, Zingarelli B, O’Connor M, Salzman AL. (1996) DNA strand breakage, activation of poly-ADP ribosyl synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. U.S.A. 93: 1753–1758.
Virág L, Scott GS, Marmer D, Cuzzocrea S, Salzman AL, Szabo C. (1998) Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly (ADP-ribose) synthetase (PARS) activation. Immunology 94: 345–355.
Ha HC, Snyder SH. (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. U.S.A. 96: 13978–13982.
Zhang J, Dawson VL, Dawson TM, Snyder SH. (1994) Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263: 687–689.
Eliasson MJ, Sampei K, Mandir AS, et al. (1997) Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 3: 1089–1095.
Zingarelli B, Salzman AL, Szabo C. (1998) Genetic disruption of poly (ADP ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia-reperfusion injury. Circ. Res. 83: 85–94.
Szabo C, Dawson VL. (1998) Role of poly (ADP-ribose) synthetase activation in inflammation and reperfusion injury. Trends Pharmacol. Sci. 19: 287–298.
Szabo C, Lim LH, Cuzzocrea S, et al. (1997) Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J. Exp. Med. 186: 1041–1049.
Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabó C. (1998) Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation. Eur. J. Pharm. 342: 67–76.
Zingarelli B, Szabo C, Salzman AL. (1999) Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116: 335–345.
Szabó C, Virág L, Cuzzocrea S, et al. (1998) Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc. Natl. Acad. Sci. U.S.A. 95: 3867–3872.
Mackay CR. (2001) Chemokines: immunology’s high impact factors. Nat. Immunol. 2: 95–101.
Hasko G, Kuhel DG, Chen JF, et al. (1999) Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14: 2065–2074.
Takeshita S, Takeshita F, Haddad DE, Ishii KJ, Klinman DM. (2000) CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell. Immunol. 206: 101–106.
Németh ZH, Mabley JG, Deitch EA, Szabó C, Haskó G. (2001) Inhibition of the Na(+)/H(+) antiporter suppresses IL-12 p40 production by mouse macrophages. Biochem. Biophys. Acta 1539: 233–242.
Haskó G, Szabó C, Németh ZH, Deitch EA. (2001) Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103: 473–478.
Gilad E, Wong HR, Zingarelli B, et al. (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J. 12: 685–693.
Szabo C, Wong H, Bauer P, et al. (1997) Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, and inhibitor of poly (ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways. Int. J. Oncol. 10: 1093–1101.
Wang ZQ, Auer B, Stingl L, et al. (1995) Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 9: 509–520.
Rath HC, Schultz M, Freitag R, et al. (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69: 2277–2285.
Liaudet L, Soriano FG, Szabo E, et al. (2000) Protection against hemorrhagic shock in mice genetically deficient in poly (ADP-ribose)polymerase. Proc. Natl. Acad. Sci. U.S.A. 97: 10203–10208.
Soriano FG, Virag L, Jagtap P, et al. (2001) Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat. Med. 7: 108–113.
Perkins E, Sun D, Nguyen A, et al. (2001) Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. 61: 4175–4183.
Oliver FJ, Menissier-de Murcia J, Nacci C, et al. (1999) Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 18: 4446–4454.
Hassa PO, Hottiger MO. (1999) A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol. Chem. 380: 953–958.
Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. (2001) The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J. Biol. Chem. 276: 45588–45597.
Chang WJ, Alvarez-Gonzalez R. (2001) The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J. Biol. Chem. 276: 47664–47670.
Ha HC, Hester LD, Snyder SH. (2002) Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. U.S.A. 99: 3270–3275.
Murphy PM. (2001) Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345: 833–835.
Horuk R. (2001) Chemokine receptors. Cytokine Growth Factor Rev. 12: 313–335.
Blease K, Lukacs NW, Hogaboam CM, Kunkel SL. (2000) Chemokines and their role in airway hyper-reactivity. Respir. Res. 1: 54–61.
Acknowledgments
We are grateful for the research support of the National Institutes of Health (R01GM60915 and R01GM66189) to C.S. and G.H. respectively.
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributed by: C. Szabó.
Rights and permissions
About this article
Cite this article
Haskó, G., Mabley, J.G., Németh, Z.H. et al. Poly(ADP-ribose) Polymerase is a Regulator of Chemokine Production: Relevance for the Pathogenesis of Shock and Inflammation. Mol Med 8, 283–289 (2002). https://doi.org/10.1007/BF03402154
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03402154